Related content

Erlotinib for elderly patients with nonsmallcell lung cancer: Subset analysis from a populationbased observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

By                                                    

Molecular and Clinical Oncology, Vol. 1, Iss. 5, 2013-01 ,pp. : 828-832

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Brain metastasis as an isolated late recurrence in smallcell lung cancer

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 2, 2014-01 ,pp. : 305-307

Spandidos Publications

Access to resources Recommend Favorite

Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 449-453

Spandidos Publications

Access to resources Recommend Favorite

ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer

By  

The Journal Of Pathology: Clinical Research, Vol. 1, Iss. 3, 2015-06 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite